The Impact of Medication Reconciliation on Discrepancies and All-Cause Readmission Among Hospitalized Patients With Chronic Kidney Disease: A Quasi-Experimental Study

Speaker(s)

Altawalbeh S1, Sallam N2, Alshogran O3, Al-Khatib M2, Bani Amer M2
1Jordan University of Science and Technology, Irbid, IR, Jordan, 2Jordan University of Science and Technology, Irbid, Jordan, 3Jordan University of Science and Technology, Ramtha, Jordan

Presentation Documents

OBJECTIVES: This study aimed to evaluate the impact of medication reconciliation supplemented with medication review on the number of medication discrepancies at discharge and all-cause readmission among CKD patients.

METHODS: This was a quasi-experimental trial among adult CKD patients admitted into two major referral hospitals in northern Jordan. Patients in the intervention group received medication reconciliation supplemented with medication review by a clinical pharmacist, while those in the control group received the usual care. The recognized discrepancies were evaluated at admission and at discharge in both groups. Participants were followed for 90-day readmission.

RESULTS: Among patients in the intervention group, the average number of discrepancies was 2.5±2.2 per CKD patient. Compared to the control group, the reduction in discrepancy numbers between admission and discharge was higher in the intervention group by 1.66 discrepancies. The likelihood of 90-day readmission was significantly lower in the intervention group (OR=0.41; P=0.002).

CONCLUSIONS: Supplemented medication reconciliation among CKD patients reveals a favorable impact on medication discrepancies and readmission rates. Optimizing medication management during transitions of care can improve overall health outcomes.

Code

HSD48

Disease

Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity), Geriatrics, Infectious Disease (non-vaccine), Urinary/Kidney Disorders